IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Warrant Agreement, dated February 8, 2021 (the “Warrant Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the Company’s initial public offering (the “IPO”), for a redemption price of $0.10 per Public Warrant (the “Redemption Price”), that remain outstanding at 5:00 p.m. New York City time on… 

Die Entwicklung der künstlichen Intelligenz (KI) hat die Arbeitskultur auf der ganzen Welt erheblich beeinflusst. KI hat Unternehmen dazu veranlasst, eine Vier-Tage-Woche einzuführen und ihren Mitarbeitern mehr Remote-Positionen anzubieten. Nach Angaben des Office for National Statistics waren im vergangenen Jahr derzeit 44 Prozent der britischen Arbeitnehmer in Positionen beschäftigt, die Remote-Kapazität bieten. Will Ahmed, der […] Dieses 3,6 Milliarden US-Dollar teure Gesundheitstechnologie-Start-up aus Boston zahlt seinen Mitarbeitern mehr Schlaf

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis https://www.cell.com/med/fulltext/S2666-6340(24)00114-4